Olaparib Monotherapy in Germline BRCA Mutation–Positive, HER2-Negative Metastatic Breast Cancer in the Real-World Setting

2021 Year in Review - HER2-Negative Breast Cancer —January 21, 2022

Categories:

Breast Cancer

Patients with germline BRCA mutation–positive, HER2-negative, advanced or metastatic breast cancer may benefit from poly (ADP-ribose) polymerase (PARP) inhibitors as a targeted treatment.1 BRCA1 and BRCA2 loss-of-function mutations are found in at least 5% of patients with unscreened breast cancer.2 In the randomized phase 3 OlympiAD study, olaparib monotherapy significantly improved progression-free survival (PFS) in patients with germline BRCA mutation–positive, HER2-negative metastatic breast cancer compared with a chemotherapy treatment of the physician’s choice.1

PARP inhibitors are drugs that disrupt PARP enzyme activity and PARylation processes, preventing DNA repair.3 Competition with nicotinamide adenine dinucleotide for interaction with the PARP catalytic domain is required for their mechanism of action.3 In 2005, 2 research groups independently discovered that PARP inhibition causes synthetic lethality in mutated BRCA1 or BRCA2 tumors, highlighting the strong relationship between BRCA and PARP inhibitors.3

Following the OlympiAD research, olaparib was approved for patients with HER2-negative metastatic breast cancer who had previously received chemotherapy.3 The phase 3 trial included 302 patients with malignancies that had genetic BRCA mutations but no HER2 overexpression, regardless of hormone receptor status (ie, estrogen receptor or progesterone receptor).3

Randomized clinical trials conducted in well-controlled environments provide solid evidence of treatment efficacy and safety.1 Their findings, however, may have limited application in clinical practice. Clinical efficacy data collected in real-world situations can help fill in the gaps in the evidence and improve knowledge of therapy benefits and drawbacks. The LUCY trial, a phase 3b study, looked at the clinical effectiveness of olaparib monotherapy in patients with BRCA mutation–positive, HER2-negative metastatic breast cancer in a setting that was meant to mimic real-world clinical practice. The results of this study showed that olaparib is efficacious in patients with germline BRCA mutation–positive, HER2-negative metastatic breast cancer. Overall, olaparib was well-tolerated, indicating that it could be a clinically useful and targeted therapeutic option for these patients with a high unmet need. Olaparib’s clinical efficacy was in line with previous findings from the phase 3 OlympiAD trial. The median PFS of the LUCY study (8.1 months) was similar to that of the olaparib arm in the OlympiAD trial at data cutoff, which was encouraging (7.0 months).1

The PARP inhibitors olaparib and talazoparib have been approved as monotherapies for deleterious and suspected deleterious germline BRCA mutation–positive, HER2-negative metastatic breast cancer.2 Olaparib is approved for metastatic breast cancer in the United States and locally advanced or metastatic breast cancer in Europe. Talazoparib is approved in the United States and Europe for locally advanced or metastatic breast cancer.2

PARP inhibitors are being studied in early breast cancer, in novel combinations, and in patients with somatic BRCA mutations and other homologous recombination repair gene alterations who do not have inherited BRCA mutations.2 PARP inhibitors in combination with immune checkpoint inhibitors are now being studied in phase 2/3 trials for the treatment of patients with triple-negative breast cancer. To identify individuals who may potentially benefit from PARP inhibitor therapy, further testing for BRCA and other mutations, as well as genetic counseling, is needed. PARP inhibitors have the potential to improve breast cancer treatment beyond the locally advanced/metastatic stage.2

References

  1. Gelmon KA, Fasching PA, Couch FJ, et al; for the Collaborating Investigators. Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis. Eur J Cancer. 2021;152:68-77.
  2. Cortesi L, Rugo HS, Jackisch C. An overview of PARP inhibitors for the treatment of breast cancer. Target Oncol. 2021;16:255-282.
  3. Faraoni I, Graziani G. Role of BRCA mutations in cancer treatment of poly(ADP-ribose) polymerase (PARP) inhibitors. Cancers (Basel). 2018;10:487.
Related Articles
Breast Cancer Screening Among Women with Comorbidities: A Cross-Sectional Examination of Disparities from the Behavioral Risk Factor Surveillance System
Ashton Gatewood, MPH, BSN, RN, Mackenzie Enmeier, BS, Elise Stephenson, BA, Jordyn Austin, BS, Benjamin Greiner, DO, MPH, Micah Hartwell, PhD
|
June 2022 Vol 13, No 6
We found that people with co-occurring diagnoses including obesity, diabetes, hypertension, skin cancer, and arthritis completed breast cancer screening more often than those with no comorbidities. Conversely, individuals living with CVD, COPD, and depression were less likely to receive potentially lifesaving breast cancer screening, suggesting biases may be present in women with these diagnoses.
What AYAs with Breast Cancer and Their Providers Tell Us About Survivorship Needs
Heather Becker, PhD, Molly McAdam, MPH, Sharyn Malatok, MPA, Emily Croce, MSN, APRN, CPNP-PC, Eunju Choi, PhD, Elaine Gonzales, CN-BA, CHW, CHWI
|
April 2022 Vol 13, No 4
Sacituzumab Govitecan-hziy in the Treatment of HR-Positive Breast Cancer
2021 Year in Review - Triple-Negative Breast Cancer
Patients with endocrine-resistant HR-positive/HER2-negative metastatic breast cancer require novel therapeutic alternatives as a result of the poor outcomes of currently available later-line medications.
Last modified: January 21, 2022

Subscribe to the Journal of Oncology Navigation & Survivorship®

To sign up for our print publication or e-newsletter, please enter your contact information below.

  • First Name *
    Last Name *
     
     
    Profession or Role
    Primary Specialty or Disease State
    Country
  • Please enter your mailing address.

    Address
     
    Address Line 2
    City
     
    State
    Zip Code